Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 370, Iss. 1, pp. 35-43
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen, Mikkel Christensen
Expert Opinion on Emerging Drugs (2021) Vol. 26, Iss. 3, pp. 231-243
Closed Access | Times Cited: 71
Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control
Paul El Meouchy, Mohamad Wahoud, Sabine Allam, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 20, pp. 12305-12305
Open Access | Times Cited: 69
A structural basis for amylin receptor phenotype
Jianjun Cao, Matthew J. Belousoff, Yi-Lynn Liang, et al.
Science (2022) Vol. 375, Iss. 6587
Closed Access | Times Cited: 48
Mediators of Amylin Action in Metabolic Control
Christina N. Boyle, Yi Zheng, Thomas A. Lutz
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2207-2207
Open Access | Times Cited: 33
AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Madeleine M. Fletcher, Peter Keov, Tin T. Truong, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 377, Iss. 3, pp. 417-440
Open Access | Times Cited: 40
Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases
Nina Sonne, M.A. Karsdal, Kim Henriksen
Molecular Metabolism (2020) Vol. 46, pp. 101109-101109
Open Access | Times Cited: 39
The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 374, Iss. 1, pp. 74-83
Open Access | Times Cited: 27
KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats
Kim Vietz Andreassen, Anna Thorsø Larsen, Nina Sonne, et al.
Molecular Metabolism (2021) Vol. 53, pp. 101282-101282
Open Access | Times Cited: 23
Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models
Anna Thorsø Larsen, Khaled Elhady Mohamed, Nina Sonne, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113842-113842
Open Access | Times Cited: 16
Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss
Anna Thorsø Larsen, Simone Anna Melander, Nina Sonne, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 164, pp. 114969-114969
Open Access | Times Cited: 7
Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss
Anna Thorsø Larsen, M.A. Karsdal, Kim Henriksen
European Journal of Pharmacology (2023) Vol. 954, pp. 175837-175837
Closed Access | Times Cited: 7
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Dimitrios Tsilingiris, Stavros Liatis, Μaria Dalamaga, et al.
Current Obesity Reports (2020) Vol. 9, Iss. 2, pp. 136-149
Open Access | Times Cited: 19
DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue
E. A. Petersen, Ida Blom, Simone Anna Melander, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 2
Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects
Igor Rubinić, Marija Kurtov, Robert Likić
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 2
The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action
Nina Sonne, Anna Thorsø Larsen, Kim Vietz Andreassen, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 373, Iss. 1, pp. 92-102
Open Access | Times Cited: 15
Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 373, Iss. 2, pp. 269-278
Open Access | Times Cited: 14
Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects
Kim Henriksen, Karen Broekhuizen, Wadim M. I. de Boon, et al.
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 12, pp. 4786-4796
Open Access | Times Cited: 12
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist Therapy
Nina Sonne, Anna Thorsø Larsen, M.A. Karsdal, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2365-2365
Open Access | Times Cited: 8
Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors
Noah B.C. Piper, Emily A. Whitfield, Gregory D. Stewart, et al.
Biochemical Pharmacology (2022) Vol. 202, pp. 115115-115115
Closed Access | Times Cited: 7
Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin
Simone Anna Melander, Anna Katri, M.A. Karsdal, et al.
European Journal of Pharmacology (2022) Vol. 938, pp. 175397-175397
Closed Access | Times Cited: 7
What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline
Karl Sebastian Johansson, David P. Sonne, Filip K. Knop, et al.
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 11, pp. 1253-1265
Closed Access | Times Cited: 10
Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide–Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C
Manuela Giansanti, Antonio De Gabrieli, Salvatore Pasquale Prete, et al.
Journal of Pharmacology and Experimental Therapeutics (2021) Vol. 377, Iss. 3, pp. 385-397
Open Access | Times Cited: 9
Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors
Sang Min Lee
Biomolecules (2021) Vol. 11, Iss. 9, pp. 1364-1364
Open Access | Times Cited: 8
Serum levels of fibrogenesis biomarkers reveal distinct endotypes predictive of response to weight loss in advanced nonalcoholic fatty liver disease
M.A. Karsdal, Kate Hallsworth, Jadine Scragg, et al.
Hepatology Communications (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 3
Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists
Raymond J. Patch, Rui Zhang, Suzanne C. Edavettal, et al.
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114330-114330
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top